^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDGFR α antagonist

    Related drugs:
    2d
    Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib response. (PubMed, Cancer Lett)
    Notably, patients harboring TP53 alterations derived clinical benefit from adjuvant lenvatinib following curative surgery. In conclusion, TDS enables effective identification of MRD-associated genomic alterations and stratifies HCC patients who may benefit from adjuvant lenvatinib, providing a molecular basis for personalized postoperative management.
    Journal • Real-world evidence • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden)
    |
    TP53 mutation
    |
    Lenvima (lenvatinib)
    2d
    Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma. (PubMed, World J Hepatol)
    Sintilimab plus lenvatinib showed heterogeneous efficacy in HCC. High LINC01554 expression, elevated CD4+ Tcm cells, and solitary tumors may serve as predictive biomarkers for prolonged disease control.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • CUX1 (cut like homeobox 1) • DFNB31 (Deafness, Autosomal Recessive 31) • FANCD2 (FA Complementation Group D2)
    |
    Tyvyt (sintilimab) • Lenvima (lenvatinib)
    4d
    Neuro-oncological ventral antigen 1 regulates liver cancer stem cell properties and Lenvatinib resistance via targeting SOX4. (PubMed, Cancer Cell Int)
    Moreover, knocking down SOX4 could reverse the NOVA1 overexpression-mediated desensitization of HCC cells to Lenvatinib-induced cell apoptosis. In summary, this investigation indicates the essential role of NOVA1 self-renew of CSCs and tumorigenesis in the liver, suggesting it as an optimal HCC therapeutic target.
    Journal
    |
    SOX4 (SRY-Box Transcription Factor 4)
    |
    Lenvima (lenvatinib)
    5d
    Activation of YBX1 and JAK2/STAT3 pathways by RIOK1 increases lenvatinib resistance in hepatocellular carcinoma cells. (PubMed, Biochim Biophys Acta Mol Cell Res)
    Tumor volume, apoptosis, KI67, YBX1, and JAK2/STAT3 phosphorylation levels were reduced in tumor tissue after RIOK1 knockdown and increased after further YBX1 overexpression. Overall, RIOK1 activates the JAK2/STAT3 pathway by promoting YBX1 phosphorylation, leading to HCC progression and lenvatinib resistance.
    Journal
    |
    YBX1 (Y-Box Binding Protein 1)
    |
    Lenvima (lenvatinib)
    6d
    LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=30, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2025
    Trial completion • Trial completion date
    |
    Lenvima (lenvatinib) • Halaven (eribulin mesylate)
    7d
    Lenvatinib-resistant liver cancer-derived HSP90α-containing extracellular vesicles enhance drug resistance via macrophage CXCL8 secretion. (PubMed, Immunol Lett)
    In conclusion, our study demonstrated that EVs containing HSP90α, derived from lenvatinib-resistant liver cancer cells, can promote EMT and drug resistance in HCC cells by stimulating CXCL8 secretion from macrophages. This finding may provide new insights and strategies to overcome lenvatinib resistance in the future.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • VIM (Vimentin) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • TLR2 (Toll Like Receptor 2)
    |
    Lenvima (lenvatinib)
    7d
    Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma. (PubMed, Auris Nasus Larynx)
    The patient was initially diagnosed with T4bN1bM1 and experienced disease progression following surgery and lenvatinib treatment. This possibility is supported by reliable evidence for the use of BRAF plus MEK inhibitor for brain metastasis from BRAF-mutated malignant melanoma. We conclude that encorafenib plus binimetinib treatment for brain metastasis from BRAF-mutated thyroid cancer is a safe and effective treatment choice.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Lenvima (lenvatinib) • Mektovi (binimetinib) • Braftovi (encorafenib)
    8d
    Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov)
    P2, N=408, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • paclitaxel • docetaxel • Lenvima (lenvatinib) • capecitabine
    8d
    Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    9d
    KEYNOTE-B61: Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (clinicaltrials.gov)
    P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    10d
    Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Universität des Saarlandes | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    11d
    A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fudan University
    New P2 trial
    |
    Lenvima (lenvatinib) • Enweida (envafolimab)